Suchergebnisse

Controversy continues about the ability of the state to promote international competitiveness of industry in general and of specific industries in particular. This study examines how the policies of the British and Japanese governments have affected the development of the pharmaceutical industries in each country. Three areas are given close attention: policies which aim to control prices or profits; patent policy; and science and technology promotion policy, particularly policies for biotechnology. Prospects for these policies are considered in the context of moves towards harmonisation of pharmaceutical regulation.

Acknowledgement Authors would like to acknowledge the financial assistance provided by the InnovateUK for this study. We would like to thank the editor, Prof Ben Martin, and three anonymous reviewers for immensely valuable feedback and advice in the preparation of this article. Our gratitude also goes to the Big Innovation Centre for supporting data collection. Also, we express our sincere thank to Dr. Zaheer Khan and Dr.George Chryssochoidis for providing us with extremely valuable gui-dance and insights to improve the paper. We are also thankful for the support of Santander Bank and Kellogg College, University of Oxford.M. De Silva et al. Research Policy 47 (2018) 70–8780 ; Peer reviewed ; Publisher PDF